Table 2.
Estimation of clinical status of sarcoidosis at follow-up visit (V2).
| V2 examinations | Score |
|---|---|
| Radiology (CXR) | 0. normal |
| 1. abnormal, improved to V1 | |
| 2. abnormal, no change to V1 | |
| 3. worse than V1 | |
| LFT (FEV1, FVC, FEV1/FVC, DLCOc) |
0. FEV1/FVC>70%, other parameters ≥ 80% predicted |
| 1. FEV1/FVC≤ 70%, at least one of the other < 80% predicted | |
| Laboratory (SACE, CRP, S-Ca2+, U-Ca2+) | 0. all within NL |
| 1. at least one out of NL | |
| Lofgren syndrome (EN, elevated BT, arthritis, oedema) | 0. absent |
| 1. present | |
| General symptoms (fatigue, weight loss, sweating, arthralgia, myalgia etc) | 0. absent |
| 1. present | |
| Respiratory symptoms (cough, breathlessness, exercise intolerance etc) | 0. absent |
| 1. present | |
| Extrapulmonary signs and symptoms | 0. absent |
| 1. present | |
Only patients with the sum of points at V2 = 0 were qualified as having complete remission. BT -- body temperature, DLCOc -- diffusion capacity for CO corrected for hemoglobin, EN -- erythema nodosum, FEV1 -- forced expiratory volume in 1st second of expiration, FVC -- forced vital capacity, LFT - lung function tests, NL -- normal; limits, S -- serum, SACE -- serum angiotensin converting enzyme, T -- time, U -- urine.